STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: PR Newswire
Executive Accountability: Stephen Pakola, M.D. Named in REGENXBIO Securities ActionNEW YORK, March 12, 2026 /PRNewswire/ -- Stephen Pakola, M.D., REGENXBIO's Executive Vice President and Chief Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing at $11.01.Find out if you qualify to recover losses from RGNX or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.Dr. Pakola's Role During the Class PeriodAs Chief Medical Officer, Dr. Pakola served as the primary spokesperson for REGENXBIO's clinical programs, including RGX-111, a gene therapy for severe Mucopolysaccharidosis Type I (MPS I). The complaint identifies Dr. Pakola as the executive who repeatedly communicated trial results to investors and the publi
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud LawsuitPR Newswire
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law FirmGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNXPR Newswire
RGNX
Earnings
- 3/5/26 - Miss
RGNX
Sec Filings
- 3/12/26 - Form 4
- 3/10/26 - Form 144
- 3/5/26 - Form 10-K
- RGNX's page on the SEC website